Remove 2023 Remove Collaboration Remove Contract research organization Remove Utilities
article thumbnail

Are You Leveraging the Drug Discovery and Early Development Outsourcing Services Ecosystem to Accelerate Growth?

Frost & Sullivan

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% growth from 2023 to 2024. What is driving transformation in the pharma industry? increase from 2022. However, the pharma/biopharma industry shows overall stagnant R&D activity.

article thumbnail

How does your company’s benchmarking performance stack up against the leading precision health companies in the ecosystem?

Frost & Sullivan

Utilize this distinctive competitive benchmarking tool to elevate your future growth potential significantly. Let us coach you on your transformational journey, while we actively support you in fostering collaborative initiatives within your industry’s ecosystem.